BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 34783596)

  • 21. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
    Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation - Real-world data from the prospective multicentre DEGUM study.
    Meitner-Schellhaas B; Jesper D; Goertz RS; Zundler S; Strobel D
    Clin Hemorheol Microcirc; 2023; 84(4):413-424. PubMed ID: 37334585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
    Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4.
    Kang HJ; Kim JH; Joo I; Han JK
    Abdom Radiol (NY); 2020 Jan; 45(1):55-63. PubMed ID: 31332503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.
    Strobel D; Jung EM; Ziesch M; Praktiknjo M; Link A; Dietrich CF; Klinger C; Schultheiß M; Jesper D; Schellhaas B
    Eur Radiol; 2021 Oct; 31(10):7614-7625. PubMed ID: 33855588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
    Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
    Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a deep-learning model for classification of LI-RADS major features by using subtraction images of MRI: a preliminary study.
    Park J; Bae JS; Kim JM; Witanto JN; Park SJ; Lee JM
    Abdom Radiol (NY); 2023 Aug; 48(8):2547-2556. PubMed ID: 37222771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.
    Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F
    Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
    Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
    AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
    [No Abstract]   [Full Text] [Related]  

  • 32. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane: LI-RADS for Diagnosing Hepatocellular Carcinoma.
    Li L; Zou X; Zheng W; Li Y; Xu X; Li K; Su Z; Han J; Li Q; Zuo Y; Xie S; Wen H; Wang J; Guo Z; Zou R; Zhou J
    Radiology; 2023 Aug; 308(2):e230150. PubMed ID: 37642573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lee S; Kim SS; Roh YH; Choi JY; Park MS; Kim MJ
    Liver Int; 2020 Jun; 40(6):1488-1497. PubMed ID: 32145134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
    Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
    Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percentages of Hepatocellular Carcinoma in LI-RADS Categories with CT and MRI: A Systematic Review and Meta-Analysis.
    Lee S; Kim YY; Shin J; Son WJ; Roh YH; Choi JY; Sirlin CB; Chernyak V
    Radiology; 2023 Apr; 307(1):e220646. PubMed ID: 36625748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
    Hwang JA; Jeong WK; Kang HJ; Lee ES; Park HJ; Lee JM
    Eur Radiol; 2022 Dec; 32(12):8507-8517. PubMed ID: 35705829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
    Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
    Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compared with CT/MRI LI-RADS, whether CEUS LI-RADS is worth popularizing in diagnosis of hepatocellular carcinoma?-a direct head-to-head meta-analysis.
    Wang H; Cao J; Fan H; Huang J; Zhang H; Ling W
    Quant Imaging Med Surg; 2023 Aug; 13(8):4919-4932. PubMed ID: 37581040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.